Rocket Pharmaceuticals has withdrawn its application seeking Food and Drug Administration approval of its RP-L102 proposed gene therapy for the treatment of the rare, inherited blood disorder Fanconi ...
Rocket Pharmaceuticals (NASDAQ:RCKT) reported that it has voluntarily withdrawn its biologics marketing application to the U.S. FDA for mozafancogene autotemcel or RP-L102, an investigational gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback